CCNK and cancer: Its dysregulation is implicated in various cancers, rendering it a promising therapeutic target.529 CR8 (225), a small molecule, acts as a molecular glue within cells, triggering Cyclin K’s ubiquitination and proteasomal degradation (Table 4).